Načítá se...
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
OBJECTIVE: Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies h...
Uloženo v:
| Vydáno v: | J Drug Assess |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7470150/ https://ncbi.nlm.nih.gov/pubmed/32939318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2020.1801452 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|